Company intelligence / Profile preview

AbGenomics

San Francisco Bay Area, California, United Stateszoominfo.com ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

AbGenomics’ lead candidate neihulizumab targets PSGL‑1 and has reached Phase 2 for autoimmune indications such as type 1 diabetes and psoriasis. The company has demonstrated safety and biological activity in early clinical trials. Additional programs are in preclinical development for oncology and immune-related diseases[2][5].

Therapeutic areas: DermatologyGastroenterologyEndocrinologyOncologyImmunology
Modalities: Antibody-drug conjugateMonoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

abgn-107

Discontinued

Partnerships

Collaborates with major pharmaceutical partners for commercialization strategy

Beyond the preview

Go deeper on AbGenomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbGenomics.

Explore the full profile